University of Illinois

Other

Invitro Diagnostics, Inc.

University of Il

Igor B Roninson

Andrei V Gudkov

Tatyana Holzmayer

Eugene Mechetner

Ilya Mazo

Choi Kyunghee

Alexander Kazarov

Preet M Chaudhary

Bey-Dih Chang

Eugene Metchetner

Alexander A Shtil

Deborah J Kirschling

Ira H Pastan

Kyunghee Choi

Michael M Gottesman

Abraham Grossman

Thomas Primiano

Adam Ruth

Tatyana A Holzmayer

Brigitte Schott

Dariusz G Tarasewicz

Milos Dokmanovic

Taixing Cui

A hybridoma (termed 'UIC2 hybridoma', ATCC Accession No. HB11027) producing monoclonal antibodies (termed 'UIC2 mAb') directed against an extracellular domain of a cell surface P-glycoprotein antigen associated with multidrug resistance in primate cells was produced by fusing a human myeloma cell with a spleen cell derived from a BALB/c mouse immunized with syngeneic 3T3 fibroblasts previously transfected with the isolated human mdr1 cDNA. UIC2 mAb, thus produced, as well as fragments and recombinant derivatives thereof, may be used to detect and isolate multidrug resistant primate cells and human mdr1 gene products, and to reverse multidrug resistance in primate cells, including cells of multidrug resistant human tumors.

Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses

The present invention provides mutant P-glycoprotein polypeptides that confer increased resistance to certain chemotherapeutic drugs relative to wild-type P-glycoprotein or P-glycoprotein having a glycine to valine substitution at position 185, and nucleic acid molecules encoding the same. The invention also provides antibodies that specifically bind mutant P-glycoproteins. The invention further provides methods for the diagnosis and treatment of conditions associated with P-glycoprotein-mediated multidrug resistance.

Mutations of the MDR1 P-glycoprotein that improves its ability to confer resistance to chemotherapeutic drugs

The invention provides methods and reagents for identifying mammalian genes necessary for tumor cell growth as targets for developing drugs that inhibit expression of said genes and inhibit tumor cell growth thereby.

Reagents and methods for identifying gene targets for treating cancer

The invention provides genetic suppressor elements that confer upon a cell resistance to one or more chemotherapeutic drug, methods for identifying and obtaining such elements, and methods of using such elements. The invention also provides cloned genes associated with sensitivity to chemotherapeutic drugs.

Genes and genetic elements associated with sensitivity to chemotherapeutic drugs

This invention identifies growth-inhibitory genes induced by retinoids. The invention provides reagents and methods for identifying compounds other than retinoids that induce expression of these cellular genes. The invention also provides reagents that are recombinant mammalian cells containing recombinant expression constructs that express a reporter gene under the transcriptional control of a promoter for a gene that is regulated by retinoids, and methods for using such cells to identify compounds other than retinoids that modulate expression of these cellular genes.

Reagents and methods for identifying and modulating expression of genes regulated by retinoids

This invention provides methods and reagents for identifying genes involved in cell cycle progression, growth promotion, modulation of apoptosis, cellular senescence and aging, and methods for identifying compounds that inhibit or potentiate cellular senescence.

Reagents and methods for identifying and modulating expression of genes regulated by p21

This invention relates to immunological reagents and methods specific for a mammalian, transmembrane protein termed Pgp, having a non-specific efflux pump activity established in the art as being a component of clinically-important multidrug resistance in cancer patients undergoing chemotherapy. The invention provides methods for developing and using immunological reagents specific for certain mutant forms of Pgp and for wild-type Pgp in a conformation associated with substrate binding or in the presence of ATP depleting agents. The invention also provides improved methods for purifying hematopoietic stems cells expressing Pgp and diagnostic and therapeutic methods for cancer cells expressing Pgp.

Methods and reagents for preparing and using immunological agents specific for P-glycoprotein

The invention provides genetic suppressor elements that confer upon a cell resistance to platinum-based drugs, including cisplatin, methods for identifying and obtaining such elements, and methods of using such elements. The invention also provides cloned genes associated with sensitivity to cisplatin.

Genes and genetic elements associated with sensitivity to platinum-based drugs

The invention provides diagnostic assays for assessing the sensitivity or resistance to DNA damaging agents and microtubule-directed chemotherapeutic drugs of malignant cells in a tumor or tissue. The assay provided involves determining gene expression levels of kinesin genes in the malignant cells, wherein under-expression of kinesin is found in cells resistant to DNA damaging agents and sensitive to microtubule-directed chemotherapeutic drugs, and over-expression of kinesin is found in cells sensitive to DNA damaging agents and resistant to microtubule-directed chemotherapeutic drugs.

Association of kinesin with sensitivity to chemotherapeutic drugs

A hybridoma (termed &ldquo;UIC2 hybridoma&rdquo;, ATCC Accession No. HB11027) producing monoclonal antibodies (termed &ldquo;UIC2 mAb&rdquo;) directed against an extracellular domain of a cell surface P-glycoprotein antigen associated with multidrug resistance in primate cells was produced by fusing a human myeloma cell with a spleen cell derived from a BALB/c mouse immunized with syngeneic 3T3 fibroblasts previously transfected with the isolated human mdrl cDNA. UIC2 mAb, thus produced, as well as fragments and recombinant derivatives thereof, may be used to detect and isolate multidrug resistant primate cells and human mdrl gene products, and to reverse multidrug resistance in primate cells, including cells of multidrug resistant human tumors.

Monoclonal antibody to a human MDR1 multidrug resistance gene product and uses

Methods for isolating and identifying genetic elements that are capable of inhibiting gene function are disclosed, as well as genetic elements isolated or identified according to the method of the invention and host cells modified by genetic modification using genetic suppressor elements according to the invention.

Methods and applications for efficient genetic suppressor elements

The invention provides genetic suppressor elements that confer upon a cell resistance to one or more chemotherapeutic drug, methods for identifying and obtaining such elements, and methods of using such elements. The invention also provides closed genes associated with sensitivity to chemotherapeutic drugs.

Gene and genetic elements associated with sensitivity to chemotherapeutic drugs

Method and applications for efficient genetic suppressor elements

The present invention is directed to methods, compositions, kits and apparatus to identify and detect the presence or absence of target analytes. The embodiments of the present invention have utility in identification of protein and measurement of its levels in specimens and samples, as well as the design of test kits and apparatus for implementing such methods.

Growing community of inventors

Wilmette, IL, United States of America

Igor B Roninson